## **Announcement Summary**

# **Entity name**

LITTLE GREEN PHARMA LTD

# **Announcement Type**

New announcement

## Date of this announcement

Tuesday November 10, 2020

# The Proposed issue is:

# Total number of +securities proposed to be issued for a placement or other type of issue

| ASX +security code | +Security description | Maximum Number of<br>+securities to be issued |
|--------------------|-----------------------|---|
| LGP                | ORDINARY FULLY PAID   | 28.784  |

# Proposed +issue date

Tuesday December 1, 2020

Refer to next page for full details of the announcement

## Part 1 - Entity and announcement details

### 1.1 Name of +Entity

LITTLE GREEN PHARMA LTD

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

## 1.2 Registered Number Type

Registration Number

ABN

55165079201

1.3 ASX issuer code

**LGP** 

1.4 The announcement is

### 1.5 Date of this announcement

Tuesday November 10, 2020

### 1.6 The Proposed issue is:

☑ A placement or other type of issue

## Part 7 - Details of proposed placement or other issue

#### Part 7A - Conditions

#### 7A.1 - Are any of the following approvals required for the placement or other type of issue?

- +Security holder approval
- Court approval
- Lodgement of court order with +ASIC
- ACCC approval
- FIRB approval
- Another approval/condition external to the entity

Yes

7A.1a Conditions

| Approval/Condition        | Date for determination | Is the date estimated or | ** Approval received/condition met? |  |
|---------------------------|------------------------|--------------------------|-------------------------------------|--|
| +Security holder approval | Thursday November 26,  | actual?                  |                                     |  |
| 3                         | 2020                   |                          | No                                  |  |

#### Comments

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?

Existing class

Will the proposed issue of this +security include an offer of attaching +securities? ☑ No

Details of +securities proposed to be issued

### ASX +security code and description

LGP: ORDINARY FULLY PAID

### Number of +securities proposed to be issued

28,784

## Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?

✓ No

| Please | describe the | consideration | being | provided f | or the | +securities |
|--------|--------------|---------------|-------|------------|--------|-------------|
|        |              |               |       |            |        |             |

Shares issued as consideration for pharmaceutical consulting services

Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities 8,698.000000

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

☑ Yes

Part 7C - Timetable

#### 7C.1 Proposed +issue date

Tuesday December 1, 2020

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?

7D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1? ☑ Yes

7D.1b (i) How many +securities are proposed to be issued without security holder approval using the entity's 15% placement capacity under listing rule 7.1?

28,784 shares

7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)? ⊗ No

7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue?

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules? 

⊗ No

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow? 

⊗ No

Part 7E - Fees and expenses

|      | 7E.1 Will there be a lead manager or broker to the proposed issue?   ⊗ No   |
|------|---|
|      | 7E.2 Is the proposed issue to be underwritten?   ☑ No   |
|      |   |
|      | 7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue |
|      |   |
| Part | 7F - Further Information  7F.01 The purpose(s) for which the entity is issuing the securities                       |
|      | As consideration for pharmaceutical consulting services   |
|      | 7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?  ☑ No             |
|      | 7F.2 Any other information the entity wishes to provide about the proposed issue                                    |
|      |   |
|      |   |